1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials

Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials

  • March 2017
  • -
  • Currentpartnering
  • -
  • 500 pages

Summary

Table of Contents

Summary
Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genetic disorders partnering deals and agreements entered into by the worlds leading healthcare companies

Description
Global Genetic Disorders Partnering 2010 to 2017 provides the full collection of Genetic Disorders disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Trends in Genetic Disorders partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Genetic Disorders partnering agreement structure
Genetic Disorders partnering contract documents
Top Genetic Disorders deals by value
Most active Genetic Disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genetic Disorders deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2010. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope
Global Genetic Disorders Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

Global Genetic Disorders Partnering 2010 to 2017 includes:
- Trends in Genetic Disorders dealmaking in the biopharma industry since 2010
- Analysis of Genetic Disorders deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Genetic Disorders deal contract documents
- Comprehensive access to over 3500 Genetic Disorders deal records
- The leading Genetic Disorders deals by value since 2010
- Most active Genetic Disorders dealmakers since 2010

The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

In Global Genetic Disorders Partnering 2010 to 2017, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genetic Disorders Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 400 genetic disorders deals.

Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Global Genetic Disorders Partnering 2010 to 2017 provides the reader with the following key benefits:
- In-depth understanding of Genetic Disorders deal trends since 2010
- Access Genetic Disorders deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Genetic Disorders partner companies
- Comprehensive access to over 750 links to actual Genetic Disorders deals entered into by the world’s biopharma companies
- Indepth review of Genetic Disorders deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Genetic Disorders opportunities
- Uncover companies actively partnering Genetic Disorders opportunities

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

  • $ 2995
  • Industry report
  • April 2017
  • by Currentpartnering

Summary The Global Biomarker Partnering Terms and Agreements 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering ...

Global Gene Therapy Partnering Terms and Agreements 2010 to 2017

Global Gene Therapy Partnering Terms and Agreements 2010 to 2017

  • $ 2995
  • Industry report
  • April 2017
  • by Currentpartnering

Summary The Global Gene Therapy Partnering Terms and Agreements 2010-2017 report provides comprehensive understanding and unprecedented access to the gene therapy partnering deals and agreements entered ...

Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017

Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017

  • $ 2995
  • Industry report
  • February 2017
  • by Currentpartnering

Summary The Global Pharmacogenomics Partnering Terms & Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the pharmacogenomics partnering deals and agreements ...


Download Unlimited Documents from Trusted Public Sources

Healthcare Industry in Kazakhstan

  • April 2017
    5 pages
  • Healthcare  

    Reproductive He...  

  • Kazakhstan  

View report >

Cancer Statistics in the US

  • April 2017
    42 pages
  • Cancer  

    Genetic  

  • United States  

View report >

Blood Disease and HIV AIDS Statistics in Africa and Malawi

  • March 2017
    22 pages
  • Blood Disease  

    HIV AIDS  

    Infectious Dise...  

  • Africa  

    Malawi  

View report >

Related Market Segments :

Genetic Disorder

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.